B. ii. The provider's usual and customary charge to the general public; or



Similar documents
Medicaid Covered Outpatient Prescription Drug Reimbursement Information by State. Quarter Ending September 2015

Prescription Drug Program

Recommendations for Medicaid Pharmacy Reimbursement for the State of Louisiana

An Update on Acquisition Cost Based Reimbursement Models. Jerry Brehany, PharmD, PA-C, JD AVP Pharmacy Services

340B Drug Discount Program Overview and Emerging Issues

C. Covered 340B drugs, as found in section 1927 (k)(2) of the Social Security Act, include the following outpatient drugs:

PHARMACY. billing module

MEDICAID DRUG PRICE COMPARISON: AVERAGE SALES PRICE TO AVERAGE WHOLESALE PRICE

(I) The following prescribed drugs are included: (a) drugs, which require a prescription, except for those drugs specifically excluded;

Overview of Drug Pricing for Public Programs

STATE 340B MEDICAID BILLING BEST PRACTICES

TEXAS VENDOR DRUG PROGRAM PHARMACY PROVIDER PROCEDURE MANUAL

Reimbursement Update: Market Changes and Proposed AMP Regulations

LEGISLATURE OF THE STATE OF IDAHO Sixty-third Legislature First Regular Session IN THE HOUSE OF REPRESENTATIVES HOUSE BILL NO.

COMPARING PHARMACY REIMBURSEMENT: MEDICARE PART D TO MEDICAID

Will the ASP data submitted to CMS be releasable to the public?

Drug Price Types and Options for a Future Standard

PHARMACY MANUAL. Walgreens Health Initiatives, Inc Half Day Road, Suite 250 Bannockburn, IL 60015

Impact of Health Reform on Prescription Drugs

Pharmacy Benefit Managers: What we do

E-ALERT Health Care HEALTH CARE REFORM: MEDICAID PRESCRIPTION DRUG REIMBURSEMENT. Executive Summary

MESSA Saver Rx PRESCRIPTION DRUG RIDER BOOKLET. Good Health. Good Business. Great Schools.

Pharmaceutical Sector and

RULES OF TENNESSEE DEPARTMENT OF LABOR AND WORKFORCE DEVELOPMENT DIVISION OF WORKERS COMPENSATION CHAPTER MEDICAL FEE SCHEDULE

The Impact of Medicare Part D on the Percent Gross Margin Earned by Texas Independent Pharmacies for Dual Eligible Beneficiary Claims

PHARMACY MANUAL. WHP Health Initiatives, Inc Half Day Road, Suite 250 Bannockburn, IL 60015

Inventory Management

Prescription Drug Pricing

North Carolina Medicaid Special Bulletin

The Basics of Pharmacy Benefits Management (PBM) 2009

General Information (Chapters 1-5) outlines the general policies and procedures applicable to all providers and payers.

MAPD-SNP Contract Numbers: H5852; H3132

Prescription drug costs continue to rise at

42 USC 256b. NB: This unofficial compilation of the U.S. Code is current as of Jan. 4, 2012 (see

Economic Report on Retail, Mail, and Specialty Pharmacies

Enclosure A DEFINITIONS

Pharmacy Operating Guidelines & Information

RULES OF TENNESSEE DEPARTMENT OF FINANCE AND ADMINISTRATION BUREAU OF TENNCARE

Medicaid and 340B. Presentation to: GHA 340B Day Presented by: Linda Wiant, Pharm.D. Pharmacy Director. Date:

The Value of OTC Medicine to the United States. January 2012

Ch AMBULANCE TRANSPORTATION 55 CHAPTER AMBULANCE TRANSPORTATION GENERAL PROVISIONS COVERED AND NONCOVERED SERVICES SCOPE OF BENEFITS

P.L.2015, CHAPTER 179, approved January 11, 2016 Senate, No (First Reprint)

Important Individual Health Plan Disclosure Information

340B Drug Pricing Program

Minimum Performance and Service Criteria for Medicare Part D

Formulary Management Best Practices

Center for Medicaid and CHIP Services Disabled and Elderly Health Programs Group. January 30, 2014

MEDICAL ASSISTANCE BULLETIN

Overview of the BCBSRI Prescription Management Program

When Public Payment Declines, Does Cost-Shifting Occur? Hospital and Physician Responses. November 13, 2002 Washington, DC

Prescription Drugs. Inside this Brief. Background Brief on

Chapter 16. Medicaid Provider Manual

Medicare Annual Enrollment Period Choice & Impact Study

Coding Systems. Understanding NDC and HCPCS. December 2014

130 CMR: DIVISION OF MEDICAL ASSISTANCE

Pharmaceutical Marketplace Dynamics Expenditures, Distribution, Coverage, Pricing

THE EXAMINER. Quarterly review of legislative and regulatory updates impacting the workers compensation and auto casualty markets.

340B Drug Pricing Program January 15, 2015

Your UC. Medical Insurance. An overview for active employees

Medical Care Advisory Committee. Andy Vasquez, Deputy Director, Medicaid/CHIP Vendor Drug Program Health and Human Services Commission

SECTION 12 - REIMBURSEMENT METHODOLOGY

CMS Publishes Final Rule Regarding Medicaid Drug Rebate Program

CMS Pharmacy Update Part 1. Current Medicaid Issues

AT&T Global Network Client for Windows Product Support Matrix January 29, 2015

Keep Your Savings: 340B Audits and Ensuring Compliance


An Overview of Wisconsin s Medical Assistance, BadgerCare, and SeniorCare Programs

Survey of Dispensing Costs of Pharmaceuticals in the State of Oregon

Analysis One Code Desc. Transaction Amount. Fiscal Period

Best Practices. How to Approach the State for Medicaid Dispute Resolution

FLORIDA WORKERS' COMPENSATION REIMBURSEMENT MANUAL FOR HOSPITALS

Princeton University Prescription Drug Plan Summary Plan Description

Sec. 340B PUBLIC HEALTH SERVICE ACT

THE COST OF EMERGENCY CONTRACEPTION: Results from a Nationwide Survey

Pharmacy Program Pre-Test

10/1/2013. Objectives. 340B Drug Pricing Program; Transitioning from Access to Integrity. 340B Stats, Arkansas. 340B Participating Entities, AR

Let s consider two situations

Session 1: Core Pharmaceutical Datasets Retail and Non Retail Laura Jenkins Jirele

WHITE PAPER The Impact of Rising Generic Drug Prices on the U.S. Drug Supply Chain

The Unintended Consequences of Restrictions on the Use of Maximum Allowable Cost Programs ( MACs ) for Pharmacy Reimbursement

Transcription:

Rev. 12/12/03 Redline Version ATTACHMENT 4.19-B The payment to an emergency room physician for the screening and assessment of a patient who receives non-emergency care in the emergency room shall not exceed the payment for a problem focused history, examination, and straight forward medical decision making. (r) The upper limits on payments for all noninstitutional items and services shall be established by the department in accordance with section 346-59, HRS, and other applicable state statutes. 3. INTENTIONALLY BLANK, renumbered as #2 in SPA 02-007. 4. PAYMENT FOR CERTAIN OTHER NON-INSTITUTIONAL ITEMS AND SERVICES: a. Payment for prescribed drugs medications: 1. Payment for ingredient cost of prescription drugs: 1. A. For single source drugs, shall not exceed the lower of: A. i. The billed chargeds; B. ii. The provider's usual and customary charge to the general public; or C. iii. The estimated acquisition cost (EAC); or or the average wholesale price (AWP) when the AWP is the average selling price, plus a reasonable dispensing fee. D. iv. The actual acquisition cost (AAC). 2. B. For multiple source drugs, shall not exceed the lower of: A. i. The billed charges; B. ii. The provider's usual and customary charge to the general public; C. iii. The estimated acquisition cost (EAC); or the average wholesale price (AWP) when the AWP is the average selling price, plus a reasonable dispensing fee. iv. The AAC; D. v. The Federal Upper Limit (FUL) price plus a reasonable dispensing fee; or E. vi. The State Maximum Allowable Cost (SMAC) plus a reasonable dispensing fee.

TN No. 02-00711- Supersedes Approval Date: April Effective Date: 10/01/02January 1, 2012 TN No. 02-00602-007-6 -

Redline Version ATTACHMENT 4.19-B 3. C. Over-The-Counter (OTC) drugs shall not exceed the lower of: Over-the-counter medications may be covered and, if covered, the payment shall be according to the methodology described in a.1. A. The billed charges; B. The provider's usual and customary charge to the general public including any sale item which may be available on the day of service; C. The allowance set by the program (State maximum allowable costs); D. The estimated acquisition cost (EAC) or the average wholesale (AWP) when the AWP is the average selling price, plus a reasonable dispensing fee; or E. The Federal Upper Limit (FUL) price plus a reasonable dispensing fee; Under no circumstances shall the program pay more than the general public for the same prescription or item. 4. Payments for medical supplies shall be made as described in section 3 (1) above. 5. D. The Federal Upper Limit (FUL) price does not apply if a physician: A. i. Certifies in his or her own handwriting, or by an electronic method approved by the State Agency, that a specific brand is medically necessary for a particular recipient. A check-off box on a form is not acceptable byut a notation of "brand medically necessary" or do not substitute" is allowable. B. ii. Obtains authorization for medical necessity from the state medical assistance program for specific brands of medication designated by the program. iii. In such cases, the payment shall not exceed the lower of: be according to the methodology described in a.1. A. The billed charge; TN No. 01-00411- Supersedes Approval Date: Jun 7 2001 Effective Date: Jan 1 2001 January 1, 2012

TN No. 99-00301-004 ATTACHMENT 4.19-B - 7 - Redline Version B. The provider's usual and customary charge to the general public; or C. The estimated acquisition cost (EAC) of the ingredient plus a reasonable dispensing fee. 6. E. The estimated acquisition cost EAC, for the purpose of this section, is defined as the lesser of the Wholesale Average Cost (WAC) or the Suggested Wholesale Price (SWP) minus 17% average wholesale price minus 10.5%. Average wholesale price will be derived from the most commonly used packaged size listed in the Bluebook. The estimated acquisition cost means the agency's best estimate of the price generally and currently paid by providers for a drug marketed or sold by a particular manufacturer or labeler in the package size of drug most frequently purchased by providers. 7. For the purpose of this section, the reasonable dispensing fee is $4.67 for claims submitted by hardcopy, electronic media claims (EMC) and Point-Of-Sale (POS). 8. F. The State maximum allowable cost (SMAC) for the purpose of this section is defined as the average of the estimated acquisition costs of the three least expensive generics available. At least one of the three products shall be provided by a manufacturer who participates in the Federal drug rebate program will be based on drug prices obtained from a nationally recognized comprehensive data file maintained by a vendor under contract with the Department agent. A generic drug may be considered SMAC for the pricing if there are two or more therapeutically equivalent, multi-source, non-innovator drugs with a cost difference. The SMAC will be based on drug status (including non-rebateable, rebateable, obsolete, therapeutic equivalency ratings, etc.), marketplace availability in Hawaii and cost. The obsolete drug status will be taken into account to ensure that the SMAC pricing is not influenced by the process listed for obsolete drugs. 9. G. Payment will not be made for innovator multiple source drugs subject to the Federal Upper Limits (42 C.F.R. 447.332(a)) when a less expensive noninnovator multiple source drug is available for dispensing from the pharmacy. Substitution may not be prohibited by Part VI, Drug Product Selection of

ATTACHMENT 4.19-B 328 HRS. 10.2. Payment of dispensing fees for prescription drugs dispensed by a licensed pharmacy: A. $5.00 per prescription. B. The dispensing fee for any maintenance or chronic medication shall be extended only once per thirty days without medical authorization from the medical assistance program. Other appropriate limits regarding the number of dispensing fees paid per interval of time shall be determined, as necessary, by the medical assistance program. TN No. 99-00311- Supersedes Approval Date: Nov 10 Effective Date: Jul 6 January 1, 2012 TN No. 87-1299-003-8 - 3. Under no circumstances shall the program pay more than the general public for the same prescription or item. 4. Payments for medical supplies shall be made as described in section 3(l) 2(k) above. 115. In compliance with section 1927(b)(2) of the Social Security Act, invoice reports will be submitted to each qualifying rebate manufacturer and the Department of Health and Human Services Secretary within sixty days after the end of each calendar quarter including information on the total number of dosage units of each covered outpatient drug dispensed under the rebate plan. This report will be consistent with the standard reporting format established by the Secretary and include the total number of dosage units of each covered outpatient drug dispensed under the plan during the quarter. b. Payments for transportation services are limited as follows: 1. Payments for ground ambulance and air ambulance services are limited to billed charges, the rate negotiated by the Department or the Medicare reasonable charge, whichever is lower. In the case of neonatal ground transportation, the upper limit on payment shall be at a rate set by the Department;

2. Except for a recipient who is a stretcher patient, payment for air transportation shall not exceed the inter-island or out-of-state airfare charged the other persons on the recipient's flight, or a contracted amount previously agreed upon between the airlines and the Department for emergency chartered flights. For transportation of a stretcher patient by the scheduled carrier, payment shall not exceed the airfare charged for four seats on the recipient's flight. 3. A round trip airfare shall be paid for an attendant whose services are recommended by the attending physician or are required by the airline. Prior approval of the Department's medical consultant is necessary, except in emergency situations, when the attending physician's authorization is sufficient, subject to the Department's medical consultant's review. In addition, payment shall be made for the attendant's service, provided the attendant is unrelated to the patient. The amount of payment for the attendant's service shall not exceed the following applicable rates: (a) Leave and return same day... $20 TN No. 01-01111- Supersedes Approval Date: Dec 20 2001 Effective Date: Oct 1, 2001 January 1, 2012 TN No. 99-00301-011-8.1 -